{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008693","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.794945+00:00","generated_at":"2026-06-17T18:22:05.520693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Celcuity Q4/FY2022 net loss $11.6M/$40.4M; cash runway extended through 2025 after $100M PIPE","bullets":["Net loss Q4 2022 $11.6M ($0.69/sh); full year net loss $40.4M ($2.64/sh).","Dosed first patient in Phase 3 VIKTORIA-1 trial, triggering $100M PIPE closing and $20M term loan drawdown.","Cash runway expected through 2025; combined with debt facility and existing cash.","Updated Phase 1b data at SABCS: median PFS 42.3 months in treatment-naive advanced breast cancer.","Enrollment ongoing in FACT-1/2 for CELsignia; interim results expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008693","json":"https://secwatch.observer/filing/0001493152-23-008693.json","markdown":"https://secwatch.observer/filing/0001493152-23-008693.md","text":"https://secwatch.observer/filing/0001493152-23-008693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/0001493152-23-008693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:22:05.520693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4687414e2d96c669b76cd4e026de9f5c92fee38a","claim":"Celcuity Inc. reported the fiscal year ended December 31, 2022 results: net income $40.4 million, EPS $2.64 loss per share.","evidence_excerpt":"Net loss for the full year 2022 was $40.4 million, or $2.64 loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/0001493152-23-008693-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"$40.4 million"},{"label":"EPS","value":"$2.64 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"537e9b3744ff1c00c73d03df78a36d6cf6858366","claim":"Celcuity Inc. reported the fourth quarter ended December 31, 2022 results: net income $11.6 million, EPS $0.69 loss per share.","evidence_excerpt":"Net loss for the fourth quarter of 2022 was $11.6 million, or $0.69 loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/0001493152-23-008693-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$11.6 million"},{"label":"EPS","value":"$0.69 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}